Clinical Trials Browser

bintrafusp alfa protein, human × 1 year × Clear all

NCT04457778 2026-05-04

First in Human Study of M6223

Phase 1 Completed

58 enrolled 38 charts

Other solid neoplasm

Metastatic Solid Tumors

NCT04708470 2026-04-06

A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers

Phase 1/2 Active not recruiting

GastrointestinalGenitourinaryGynecologicHead & Neck

Anus Neoplasms, Uterine Cervical Neoplasms, Colonic Neoplasms, Head and Neck Neoplasms, Oropharyngeal Neoplasms, Penile Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms

NCT04789668 2026-03-18

Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases

Phase 1/2 Terminated

8 enrolled 13 charts

BreastCNSDermatologicOther hematologic neoplasmThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Hematologic Neoplasms, Triple Negative Breast Neoplasms

NCT04708067 2026-03-05

Hypofractionated Radiation Therapy and Bintrafusp Alfa for the Treatment of Advanced Intrahepatic Cholangiocarcinoma

Phase 1 Active not recruiting

Gastrointestinal

Cholangiocarcinoma

NCT05061823 2026-02-02

Bintrafusp Alfa Program Rollover Study

Phase 3 Completed

22 enrolled 11 charts

Lung Neoplasms, Neoplasms

NCT05005429 2025-12-23

BIMES

Phase 2 Completed

47 enrolled 9 charts

Other solid neoplasmThoracic

Mesothelioma, Malignant, Mesothelioma

NCT04396535 2025-11-17

Docetaxel With or Without Bintrafusp Alfa for the Treatment of Advanced Non-small Cell Lung Cancer

Phase 2 Terminated

10 enrolled 17 charts

Lung Neoplasms

NCT03493945 2025-09-30

Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat (QuEST1)

Phase 1/2 Completed

59 enrolled 20 charts

Prostatic Neoplasms

NCT04874311 2025-08-13

TRUST

Phase 2 Recruiting

Tertiary Lymphoid Structures, Neoplasm Metastasis, Sarcoma

NCT04247282 2025-07-16

Anti-PD-L1/TGF-beta Trap (M7824) Alone and in Combination With TriAd Vaccine and N-803 for Resectable Head and Neck Squamous Cell Carcinoma Not Associated With Human Papillomavirus Infection

Phase 1/2 Completed

21 enrolled 16 charts

Head and Neck Neoplasms